Dr. Michael C. Cameron

Medicare patients and services

Medicare patients, 2024

537

Services billed

8,887

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 806 payments worth $737,247 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 20 industry-funded studies in 2025, from 6 companies. The companies reported $2,787,766 in research payments for these studies, mostly to the institutions running them.

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  Sanofi US Services Inc. · Active, not recruiting · NCT06241118
• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
  Sanofi US Services Inc. · Active, not recruiting · NCT06407934
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
  Eli Lilly and Company · Completed · NCT06588283
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
  Sanofi US Services Inc. · Completed · NCT06181435
• A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
  Novartis Pharmaceuticals Corporation
• A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
  Sanofi US Services Inc. · Completed · NCT06687967
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
  Sanofi US Services Inc. · Completed · NCT06224348
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  AbbVie Inc. · Active, not recruiting · NCT06389136
• A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
  AbbVie Inc. · Active, not recruiting · NCT06718101
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
  AbbVie Inc. · Recruiting · NCT06012240

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in New York

• Brian J. Abittan, M.D.
• Jonas A. Adalsteinsson, MD
• Natnaelle E. Admassu, MD, MS
• Prince U. Adotama, M.D.
• Ian M. Ahearn, M.D.
• Jesleen Ahluwalia, M.D.
• Jeffrey L. Ainspan, M.D.
• Lisa E. Airan, MD